ArticleHead and neck pathology2025
Molecular Analysis in Salivary Gland Tumors: Exploring the Diagnostic and Clinical Impact of Comprehensive Next Generation RNA Sequencing ("SalvGlandDx v2").
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic yield and clinical impact of a comprehensive RNA-based sequencing panel ("SalvGlandDx version 2") in the work-up of salivary gland tumors.
methodsBetween 2021 and 2025, 118 salivary gland tumors were assessed by routine histological and immunohistochemical investigation, followed by SalvGlandDx v2 RNA sequencing. This panel targets the recurrent molecular alterations in salivary gland neoplasms. Pre- and post-sequencing (differential) diagnoses were compared to determine the diagnostic contribution, categorized as diagnostic confirmation (1 A), refinement (1B/2A/2B) or no impact (3). Clinical impact was scored as none (A), altered follow-up (B), radiotherapy indication (C) and/or systemic therapy (D) when comparing pre- and post-sequencing (differential) diagnoses.
resultsRNA sequencing was successful in 114 of 118 cases (97%). Molecular alterations were detected in 78 of 114 cases (68%), most commonly involving rearrangements of PLAG1 and HMGA2 in (carcinoma ex) pleomorphic adenoma, and MAML2 in mucoepidermoid carcinoma. Diagnostic refinement was achieved in 66 of 114 cases (58%), including 29 cases (25%) with confirmation of the pre-sequencing diagnosis and 37 cases (32%) with refinement of the pre-sequencing differential diagnosis. Clinical management was impacted in 29 of 114 patients (25%), most often affecting follow-up frequency.
conclusionComprehensive SalvGlandDx v2 RNA sequencing demonstrated high feasibility and substantial diagnostic and clinical utility in salivary gland tumors, resolving morphological and immunohistochemically ambiguous cases. In a subset of patients, use of the analysis also influenced clinical management highlighting the value of integrating RNA sequencing into routine diagnostic work-up of the varied and challenging salivary gland tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.